Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human intranasal GSK2245035 in healthy volunteers and allergic rhinitis participants
NL-OMON36044Phase 1Active, not recruiting
- Sponsor
- GSK
- Start
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in allergic rhinitis (AR) comparing GSK2245035 with Placebo (2 arms). Primary endpoints: Safety and nasal tolerability and Nasal tissue pharmacodynamic biomarkers in allergic rhinitis participants. Started Jun 2011; status: active, not recruiting.
02
Drugs
GSK2245035
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NL-OMON36044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36044.